Celcuity Faces Widening Losses as Analysts Await Critical Earnings Report

Celcuity Inc reports fourth-quarter fiscal 2025 earnings after market close on March 25, 2026. With analysts expecting losses to deepen and the stock trading below most short-term moving averages, investors face a critical test of whether the company's clinical-stage pipeline can justify its current valuation amid mounting cash burn concerns.

Part 1: Earnings Preview

Celcuity Inc is a clinical-stage biotechnology company focused on developing targeted therapies for cancer patients, with its lead programs targeting specific cellular signaling pathways in breast and other solid tumors. The company's value proposition centers on its proprietary diagnostic platform that identifies patients most likely to respond to its investigational treatments.

Celcuity is scheduled to report fourth-quarter fiscal 2025 results after the close on March 25, 2026. Analysts expect an EPS loss of -$1.06 on four estimates, compared to the -$0.92 loss reported in the most recent quarter (September 2025). Year-over-year, the consensus represents a 24.71% deterioration from the -$0.85 loss posted in the same quarter last year (December 2024).

Three key themes define this earnings story:

Clinical Trial Progress and Enrollment: Investors will scrutinize updates on patient enrollment rates and any preliminary efficacy signals from ongoing Phase 2/3 studies. The pace of clinical development directly impacts the company's timeline to potential commercialization and determines how long current cash reserves must sustain operations.

Cash Runway and Burn Rate: With widening quarterly losses, the quarterly cash consumption rate and remaining runway before potential dilutive financing becomes critical. Analysts are watching whether operational efficiencies can extend the runway or if capital raises will be necessary sooner than anticipated.

Regulatory Pathway Clarity: Any commentary on interactions with the FDA regarding trial design, endpoints, or accelerated approval pathways could significantly impact investor confidence. Clearer regulatory visibility would help validate the commercial potential of the pipeline and justify the current market valuation.

Analyst commentary ahead of the release reflects cautious optimism tempered by near-term execution concerns. The consensus of 9 strong buys, 1 moderate buy, and 2 holds among 12 analysts suggests confidence in the long-term opportunity, though the widening loss estimates indicate near-term headwinds are expected to persist.

Part 2: Historical Earnings Performance

Celcuity's recent earnings history reveals an inconsistent pattern of beats and misses with significant magnitude swings. Over the past four quarters, the company has alternated between positive and negative surprises, suggesting difficulty in establishing predictable cost structures typical of clinical-stage biotechnology firms.

The most recent quarter (September 2025) delivered a +12.38% beat, reporting -$0.92 versus the -$1.05 estimate. However, this followed a -15.56% miss in June 2025 when the company reported -$1.04 against a -$0.90 estimate. The March 2025 quarter showed a +9.47% beat (-$0.86 vs -$0.95 expected), while December 2024 missed by -18.06% (-$0.85 vs -$0.72 expected).

The volatility in these results—ranging from an 18% miss to a 12% beat—reflects the lumpy nature of clinical trial expenses and the difficulty analysts face in modeling R&D spending timing. With losses deepening on a year-over-year basis and estimates trending wider for both the current and next quarter, the pattern suggests accelerating investment in clinical programs that may pressure near-term results even as they advance the pipeline.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Celcuity reports after market close, meaning Day 0 captures anticipatory trading before results are released, while Day +1 reflects the market's first full session to digest the actual numbers.

Historical price action shows significant volatility around Celcuity earnings releases, with the Day +1 reaction typically exceeding the Day 0 move. The average absolute Day 0 move of 2.79% jumps to 5.95% by Day +1, indicating that the market's initial assessment often shifts substantially once investors fully process the results and management commentary. The most dramatic example occurred in March 2024, when a modest 3.65% Day 0 gain exploded into an 18.94% surge on Day +1. Conversely, November 2024 saw a relatively contained 3.62% Day 0 decline expand to a 10.28% drop the following session. The wide Day +1 average range of 14.07% underscores the binary nature of investor reactions to clinical-stage biotech updates, where pipeline progress or setbacks can trigger outsized moves.

Part 2.2: Options Market Expected Move

The options market is pricing a 12.59% expected move for the upcoming earnings release, which sits well above the 2.79% average Day 0 move but substantially above the 5.95% average Day +1 move. This elevated implied volatility suggests options traders are anticipating a more significant reaction than the historical average, potentially reflecting heightened uncertainty around clinical trial updates or cash runway concerns that could drive a larger-than-typical post-earnings swing.

Part 3: What Analysts Are Saying

Analyst sentiment on Celcuity remains strongly bullish despite the near-term loss trajectory. The current consensus shows 9 strong buy ratings, 1 moderate buy, and 2 holds among 12 covering analysts, with zero sell ratings. This distribution has remained stable over the past month, indicating conviction in the long-term thesis has not wavered despite widening loss estimates.

The average price target of $120.90 implies 18.5% upside from the current price of $102.01, with a wide range spanning from a low target of $94.00 to a high of $155.00. This 65-point spread reflects divergent views on the probability and timeline of clinical success, with the high-end target suggesting some analysts see potential for the stock to appreciate more than 50% if pipeline milestones are achieved.

The unchanged rating distribution over the past month—with the average recommendation holding steady at 4.58 on a 5-point scale—suggests analysts are maintaining their positions heading into this report rather than adjusting ahead of the release. The concentration of strong buy ratings indicates most analysts view current levels as an attractive entry point despite the near-term cash burn, likely betting that positive clinical data could serve as a significant catalyst.

Part 4: Technical Picture

The Barchart Technical Opinion currently shows a 40% Buy signal, representing a significant deterioration from 100% Buy one week ago and 72% Buy one month ago. This rapid weakening in technical momentum heading into earnings reflects recent price pressure that has pushed the stock below multiple near-term moving averages.

Timeframe Analysis:

• Short-term (50% Buy): Moderate buy signal indicates near-term momentum has weakened but remains marginally positive
• Medium-term (50% Buy): Neutral-to-positive reading suggests the intermediate trend is at an inflection point
• Long-term (50% Buy): Moderate buy signal reflects the longer-term uptrend remains intact despite recent pullback

Trend Characteristics: The Soft strength with Weakest direction indicates a fragile technical environment where momentum has deteriorated to its lowest point in the recent trend, suggesting vulnerability heading into the earnings catalyst.

Celcuity currently trades at $102.01, positioned below the 5-day ($108.06), 10-day ($111.01), 20-day ($111.45), and 50-day ($109.35) moving averages, indicating short-term downward pressure. However, the stock remains above the 100-day ($102.24) and well above the 200-day ($70.59) moving average, confirming the longer-term uptrend remains intact despite the recent 8-9% pullback from the $111 area.

The stock is testing support at the 100-day moving average, a critical technical level that has historically provided a floor during pullbacks. A break below $102.24 could trigger further technical selling toward the psychological $100 level, while a hold above this support combined with positive earnings news could spark a recovery back toward the $109-$111 resistance zone. The deteriorating short-term momentum and positioning below all near-term averages creates a cautious technical setup, where the earnings release will likely determine whether this represents a buyable dip or the start of a deeper correction.